CoChat
Sign Up
Cited by 88Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesNonmelanoma Skin Cancer Studies

Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors

Open access
Yakkala, Chakradhar, Chiang, Cheryl Lai-Lai, Kandalaft, Lana, Denys, Alban, Duran, Rafael·2019·Frontiers in Immunology
DOI 10.3389/fimmu.2019.02283PMC PMC6769045
Open this paper in CoChat — free accountOpen PDF

Abstract

Treatment of solid tumors by ablation techniques has gained momentum in the recent years due to their technical simplicity and reduced morbidity as juxtaposed to surgery. Cryoablation is one of such techniques, known for its uniqueness to destroy the tumors by freezing to lethal temperatures. Freezing the tumor locally and allowing it to remain in situ unleashes an array of tumor antigens to be exposed to the immune system, paving the way for the generation of anti-tumor immune responses. However, the immune responses triggered in most cases are insufficient to eradicate the tumors with systemic spread. Therefore, combination of cryoablation and immunotherapy is a new treatment strategy currently being evaluated for its efficacy, notably in patients with metastatic disease. This article examines the mechanistic fabric of cryoablation for the generation of an effective immune response against the tumors, and various possibilities of its combination with different immunotherapies that are capable of inducing exceptional therapeutic responses. The combinatorial treatment avenues discussed in this article if explored in sufficient profundity, could reach the pinnacle of future cancer medicine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2019.02283

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Clinical outcomes of tumor cryoablation-both obtaining local control and achieving an abscopal effect-are highly unpredictable with variable magnitudes of response and frequent failure of local recurrence.

    “Despite these theoretical benefits, clinical outcomes of tumor cryoablation—both obtaining local control and achieving an abscopal effects—are highly unpredictable with variable magnitudes of response and frequent failure of local recurrence.”

    From Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation (2023) · cites this paper as [77]

    The ‘Critical Aspects’ section (page unavailable) says some patients experience local tumor progression after cryoablation and that factors governing its effects remain ill-defined. The ‘Immunology of Cryoablation’ section (page unavailable) describes variable immune responses and limited abscopal regression. These passages support uncertainty in outcomes, but the source says only a fraction of patients have local progression, not that local failure is frequent. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 113 · Cited by 88

Research works printed but not linked: 106

  1. [1]Escudier B Porta C Schmidinger M Rioux-Leclercq N Bex A Khoo V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2016) 27: v58– 68. 10.1093/annonc/mdw328 27664262 · DOI
  2. [2]European Association for the Study of the Liver Electronic address eee, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. (2018) 69: 182– 236. 10.1016/j.jhep.2018.03.024 29628281 · DOI
  3. [3]Chapman WC Debelak JP Wright Pinson C Washington MK Atkinson JB Venkatakrishnan A Hepatic cryoablation, but not radiofrequency ablation, results in lung inflammation. Ann Surg. (2000) 231: 752– 61. 10.1097/00000658-200005000-00016 10767797 PMC1421063 · DOI
  4. [4]Jansen MC van Hillegersberg R Schoots IG Levi M Beek JF Crezee H Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery. (2010) 147: 686– 95. 10.1016/j.surg.2009.10.053 20042207 · DOI
  5. [5]Erinjeri JP Thomas CT Samoilia A Fleisher M Gonen M Sofocleous CT. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J Vasc Interv Radiol. (2013) 24: 1105– 12. 10.1016/j.jvir.2013.02.015 23582441 PMC4167629 · DOI
  6. [6]Shao Q O'Flanagan S Lam T Roy P Pelaez F Burbach BJ. Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. Int J Hyperthermia. (2019) 36: 130– 8. 10.1080/02656736.2018.1539253 30676126 · DOI
  7. [7]Gage AA Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. (1998) 37: 171– 86. 10.1006/cryo.1998.2115 9787063 · DOI
  8. [8]Sidana A Chowdhury WH Fuchs EJ Rodriguez R. Cryoimmunotherapy in urologic oncology. Urology. (2010) 75: 1009– 14. 10.1016/j.urology.2009.06.020 19758686 · DOI
  9. [9]Korpan NN. A history of cryosurgery: its development and future. J Am Coll Surg. (2007) 204: 314– 24. 10.1016/j.jamcollsurg.2006.11.006 17254936 · DOI
  10. [10]Cooper SM Dawber RP. The history of cryosurgery. J R Soc Med. (2001) 94: 196– 201. 10.1177/014107680109400416 11317629 PMC1281398 · DOI
  11. [11]Allington HV. Liquid nitrogen in the treatment of skin diseases. Calif Med. (1950) 72: 153– 5. 15410141 PMC1520330
  12. [12]Rowbotham GF Haigh AL Leslie WG. Cooling cannula for use in the treatment of cerebral neoplasms. Lancet. (1959) 1: 12– 5. 10.1016/S0140-6736(59)90976-6 13612232 · DOI
  13. [13]Cooper IS Lee AS Cryostatic congelation: a system for producing a limited, controlled region of cooling or freezing of biologic tissues. J Nerv Ment Dis. (1961) 133: 259– 63. 10.1097/00005053-196109000-00013 13881139 · DOI
  14. [15]Erinjeri JP Clark TW. Cryoablation: mechanism of action and devices. J Vasc Interv Radiol. (2010) 21: S187– 91. 10.1016/j.jvir.2009.12.403 20656228 PMC6661161 · DOI
  15. [16]Gage AA Baust JM Baust JG. Experimental cryosurgery investigations in vivo. Cryobiology. (2009) 59: 229– 43. 10.1016/j.cryobiol.2009.10.001 19833119 PMC2821701 · DOI
  16. [17]Mazur P. Freezing of living cells: mechanisms and implications. Am J Physiol. (1984) 247: C125– 42. 10.1152/ajpcell.1984.247.3.C125 6383068 · DOI
  17. [18]Hoffmann NE Bischof JC. The cryobiology of cryosurgical injury. Urology. (2002) 60: 40– 9. 10.1016/S0090-4295(02)01683-7 12206847 · DOI
  18. [19]Bryant G. DSC measurement of cell suspensions during successive freezing runs: implications for the mechanisms of intracellular ice formation. Cryobiology. (1995) 32: 114– 28. 10.1006/cryo.1995.1011 7743814 · DOI
  19. [20]Mazur P. Kinetics of water loss from cells at subzero temperatures and the likelihood of intracellular freezing. J Gen Physiol. (1963) 47: 347– 69. 10.1085/jgp.47.2.347 14085017 PMC2195343 · DOI
  20. [21]Gage AA Meenaghan MA Natiella JR Greene GW Jr. Sensitivity of pigmented mucosa and skin to freezing injury. Cryobiology. (1979) 16: 348– 61. 10.1016/0011-2240(79)90048-8 487851 · DOI
  21. [22]Baust JG Gage AA. Progress toward optimization of cryosurgery. Technol Cancer Res Treat. (2004) 3: 95– 101. 10.1177/153303460400300202 15059015 · DOI
  22. [23]Zhou T Li Q Chi X Li L Rao J Hu K. 0 degrees C is better?- Thawing temperature optimization study for cancer cryoablation in a mouse model with green fluorescent protein-labeled Lewis lung cancer. Cryobiology. (2017) 75: 80– 7. 10.1016/j.cryobiol.2017.01.008 28137430 · DOI
  23. [24]Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology. (2009) 58: 1– 11. 10.1016/j.cryobiol.2008.10.126 19007768 · DOI
  24. [25]Theodorescu D. Cancer cryotherapy: evolution and biology. Rev Urol. (2004) 6(Suppl. 4): S9– 19. 10.1186/1475-2867-4-S1-S19 16985871 PMC1472868 · DOI
  25. [26]Takahashi Y Izumi Y Matsutani N Dejima H Nakayama T Okamura R. Optimized magnitude of cryosurgery facilitating anti-tumor immunoreaction in a mouse model of Lewis lung cancer. Cancer Immunol Immunother. (2016) 65: 973– 82. 10.1007/s00262-016-1858-x 27312061 PMC11029219 · DOI
  26. [27]Chu KF Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. (2014) 14: 199– 208. 10.1038/nrc3672 24561446 · DOI
  27. [28]Maccini M Sehrt D Pompeo A Chicoli FA Molina WR Kim FJ. Biophysiologic considerations in cryoablation: a practical mechanistic molecular review. Int Braz J Urol. (2011) 37: 693– 6. 10.1590/S1677-55382011000600002 22233999 · DOI
  28. [29]Alblin RJ Soanes WA Gonder MJ. Prospects for cryo-immunotherapy in cases of metastasizing carcinoma of the prostate. Cryobiology. (1971) 8: 271– 9. 10.1016/0011-2240(71)90050-2 5570410 · DOI
  29. [30]Gursel E Roberts M Veenema RJ. Regression of prostatic cancer following sequential cryotherapy to the prostate. J Urol. (1972) 108: 928– 32. 10.1016/S0022-5347(17)60909-1 4117196 · DOI
  30. [31]Soanes WA Ablin RJ Gonder MJ. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol. (1970) 104: 154– 9. 10.1016/S0022-5347(17)61690-2 4987666 · DOI
  31. [32]Uhlschmid G Kolb E Largiader F. Cryosurgery of pulmonary metastases. Cryobiology. (1979) 16: 171– 8. 10.1016/0011-2240(79)90028-2 477364 · DOI
  32. [33]Misao A Sakata K Saji S Kunieda T. Late appearance of resistance to tumor rechallenge following cryosurgery. A study in an experimental mammary tumor of the rat. Cryobiology. (1981) 18: 386– 9. 10.1016/0011-2240(81)90111-5 7307529 · DOI
  33. [34]Miya K Saji S Morita T Niwa H Takao H Kida H. Immunological response of regional lymph nodes after tumor cryosurgery: experimental study in rats. Cryobiology. (1986) 23: 290– 5. 10.1016/0011-2240(86)90034-9 3743106 · DOI
  34. [35]Neel HB 3rd Ketcham AS Hammond WG. Experimental evaluation of in situ oncocide for primary tumor therapy: comparison of tumor-specific immunity after complete excision, cryonecrosis and ligation. Laryngoscope. (1973) 83: 376– 87. 10.1288/00005537-197303000-00009 4690029 · DOI
  35. [36]Sabel MS Nehs MA Su G Lowler KP Ferrara JL Chang AE. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat. (2005) 90: 97– 104. 10.1007/s10549-004-3289-1 15770533 · DOI
  36. [37]Sabel MS Arora A Su G Chang AE. Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor. Cryobiology. (2006) 53: 360– 6. 10.1016/j.cryobiol.2006.07.004 16973145 · DOI
  37. [38]den Brok MH Sutmuller RP Nierkens S Bennink EJ Toonen LW Figdor CG. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. (2006) 66: 7285– 92. 10.1158/0008-5472.CAN-06-0206 16849578 · DOI
  38. [39]Osada S Imai H Tomita H Tokuyama Y Okumura N Matsuhashi N. Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol. (2007) 95: 491– 8. 10.1002/jso.20712 17219394 · DOI
  39. [40]Beatty GL Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. (2015) 21: 687– 92. 10.1158/1078-0432.CCR-14-1860 25501578 PMC4334715 · DOI · Paper page
  40. [41]Otto G. Tumour decides immune cell ins and outs. Nat Rev Immunol. (2018) 18: 481. 10.1038/s41577-018-0038-y 29985485 · DOI
  41. [42]Seton-Rogers S. Oncogenes: driving immune evasion. Nat Rev Cancer. (2018) 18: 67. 10.1038/nrc.2018.5 29368742 · DOI
  42. [43]Kaczanowska S Joseph AM Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. (2013) 93: 847– 63. 10.1189/jlb.1012501 23475577 PMC3656332 · DOI
  43. [44]Kawasaki T Kawai T. Toll-like receptor signaling pathways. Front Immunol. (2014) 5: 461. 10.3389/fimmu.2014.00461 25309543 PMC4174766 · DOI
  44. [45]Redondo P del Olmo J Lopez-Diaz de Cerio A Inoges S Marquina M Melero I. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol. (2007) 127: 1673– 80. 10.1038/sj.jid.5700777 17380112 · DOI
  45. [46]Gaitanis G Nomikos K Vava E Alexopoulos EC Bassukas ID. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application. J Eur Acad Dermatol Venereol. (2009) 23: 1427– 31. 10.1111/j.1468-3083.2009.03224.x 19555364 · DOI
  46. [48]Gardner A Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. (2016) 37: 855– 65. 10.1016/j.it.2016.09.006 27793569 PMC5135568 · DOI
  47. [49]Bevan MJ Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. (1976) 143: 1283– 8. 10.1084/jem.143.5.1283 1083422 PMC2190184 · DOI
  48. [50]Garg AD Coulie PG Van den Eynde BJ Agostinis P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. (2017) 38: 577– 93. 10.1016/j.it.2017.05.006 28610825 · DOI · Paper page
  49. [51]Constantino J Gomes C Falcao A Cruz MT Neves BM. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. Transl Res. (2016) 168: 74– 95. 10.1016/j.trsl.2015.07.008 26297944 · DOI
  50. [52]Anguille S Smits EL Lion E van Tendeloo VF Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. (2014) 15: e257– 67. 10.1016/S1470-2045(13)70585-0 24872109 · DOI
  51. [53]Machlenkin A Goldberger O Tirosh B Paz A Volovitz I Bar-Haim E. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin Cancer Res. (2005) 11: 4955– 61. 10.1158/1078-0432.CCR-04-2422 16000595 · DOI
  52. [54]Udagawa M Kudo-Saito C Hasegawa G Yano K Yamamoto A Yaguchi M. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res. (2006) 12: 7465– 75. 10.1158/1078-0432.CCR-06-1840 17189420 · DOI
  53. [55]Lowry LE Zehring WA. Potentiation of natural killer cells for cancer immunotherapy: a review of literature. Front Immunol. (2017) 8: 1061. 10.3389/fimmu.2017.01061 28919894 PMC5585139 · DOI
  54. [56]Rezvani K Rouce R Liu E Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. (2017) 25: 1769– 81. 10.1016/j.ymthe.2017.06.012 28668320 PMC5542803 · DOI
  55. [57]Imai K Matsuyama S Miyake S Suga K Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. (2000) 356: 1795– 9. 10.1016/S0140-6736(00)03231-1 11117911 · DOI
  56. [58]Rezvani K Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol. (2015) 6: 578. 10.3389/fimmu.2015.00578 26635792 PMC4648067 · DOI
  57. [59]Iliopoulou EG Kountourakis P Karamouzis MV Doufexis D Ardavanis A Baxevanis CN. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. (2010) 59: 1781– 9. 10.1007/s00262-010-0904-3 20703455 PMC11030924 · DOI
  58. [60]Lin M Liang S Wang X Liang Y Zhang M Chen J. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. Oncotarget. (2017) 8: 81967– 77. 10.18632/oncotarget.17804 29137237 PMC5669863 · DOI
  59. [61]Lin M Liang SZ Wang XH Liang YQ Zhang MJ Niu LZ. Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res. (2017) 65: 880– 7. 10.1007/s12026-017-8927-x 28508945 · DOI
  60. [62]Lin M Xu K Liang S Wang X Liang Y Zhang M. Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer. Immunol Lett. (2017) 184: 98– 104. 10.1016/j.imlet.2017.03.004 28274792 · DOI
  61. [63]Gao X Mi Y Guo N Xu H Xu L Gou X. Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy. Front Immunol. (2017) 8: 774. 10.3389/fimmu.2017.00774 28729866 PMC5498561 · DOI
  62. [64]Liu L Zhang W Qi X Li H Yu J Wei S. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. (2012) 18: 1751– 9. 10.1158/1078-0432.CCR-11-2442 22275504 · DOI
  63. [65]Pan K Guan XX Li YQ Zhao JJ Li JJ Qiu HJ. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res. (2014) 20: 3003– 11. 10.1158/1078-0432.CCR-14-0082 24668644 · DOI
  64. [66]Lee JH Lee JH Lim YS Yeon JE Song TJ Yu SJ. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. (2015) 148: 1383– 91 e1386. 10.1053/j.gastro.2015.02.055 25747273 · DOI · Paper page
  65. [67]Niu LZ Li JL Zeng JY Mu F Liao MT Yao F. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol. (2013) 19: 3473– 80. 10.3748/wjg.v19.i22.3473 23801841 PMC3683687 · DOI
  66. [68]Niu L Chen J He L Liao M Yuan Y Zeng J. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas. (2013) 42: 1143– 9. 10.1097/MPA.0b013e3182965dde 23899940 · DOI
  67. [69]Yuanying Y Lizhi N Feng M Xiaohua W Jianying Z Fei Y. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology. (2013) 67: 235– 40. 10.1016/j.cryobiol.2013.08.001 23948179 · DOI
  68. [70]Silva-Santos B Serre K Norell H. gammadelta T cells in cancer. Nat Rev Immunol. (2015) 15: 683– 91. 10.1038/nri3904 26449179 · DOI · Paper page
  69. [71]Lo Presti E Pizzolato G Gulotta E Cocorullo G Gulotta G Dieli F. Current advances in gammadelta T cell-based tumor immunotherapy. Front Immunol. (2017) 8: 1401. 10.3389/fimmu.2017.01401 29163482 PMC5663908 · DOI
  70. [72]Pauza CD Liou ML Lahusen T Xiao L Lapidus RG Cairo C. Gamma delta T cell therapy for cancer: it is good to be local. Front Immunol. (2018) 9: 1305. 10.3389/fimmu.2018.01305 29937769 PMC6003257 · DOI
  71. [73]Gober HJ Kistowska M Angman L Jeno P Mori L De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. (2003) 197: 163– 8. 10.1084/jem.20021500 12538656 PMC2193814 · DOI
  72. [74]Chargui J Combaret V Scaglione V Iacono I Peri V Valteau-Couanet D. Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells. J Immunother. (2010) 33: 591– 8. 10.1097/CJI.0b013e3181dda207 20551838 · DOI
  73. [75]Zhou J Kang N Cui L Ba D He W. Anti-gammadelta TCR antibody-expanded gammadelta T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cell Mol Immunol. (2012) 9: 34– 44. 10.1038/cmi.2011.16 21666706 PMC4002925 · DOI
  74. [76]Brandes M Willimann K Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science. (2005) 309: 264– 8. 10.1126/science.1110267 15933162 · DOI
  75. [77]Fisher JP Heuijerjans J Yan M Gustafsson K Anderson J. gammadelta T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology. (2014) 3: e27572. 10.4161/onci.27572 24734216 PMC3984269 · DOI
  76. [78]Bennouna J Bompas E Neidhardt EM Rolland F Philip I Galea C. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. (2008) 57: 1599– 609. 10.1007/s00262-008-0491-8 18301889 PMC11030608 · DOI
  77. [79]Sakamoto M Nakajima J Murakawa T Fukami T Yoshida Y Murayama T Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadelta T cells: a phase I clinical study. J Immunother. (2011) 34: 202– 11. 10.1097/CJI.0b013e318207ecfb 21304399 · DOI
  78. [80]Nicol AJ Tokuyama H Mattarollo SR Hagi T Suzuki K Yokokawa K. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer. (2011) 105: 778– 86. 10.1038/bjc.2011.293 21847128 PMC3171009 · DOI
  79. [81]Fleming C Morrissey S Cai Y Yan J. Gammadelta T cells: unexpected regulators of cancer development and progression. Trends Cancer. (2017) 3: 561– 70. 10.1016/j.trecan.2017.06.003 28780933 PMC5551453 · DOI
  80. [82]Parente-Pereira AC Shmeeda H Whilding LM Zambirinis CP Foster J van der Stegen SJ. Adoptive immunotherapy of epithelial ovarian cancer with Vgamma9Vdelta2 T cells, potentiated by liposomal alendronic acid. J Immunol. (2014) 193: 5557– 66. 10.4049/jimmunol.1402200 25339667 · DOI
  81. [83]Santolaria T Robard M Leger A Catros V Bonneville M Scotet E. Repeated systemic administrations of both aminobisphosphonates and human Vgamma9Vdelta2 T cells efficiently control tumor development in vivo. J Immunol. (2013) 191: 1993– 2000. 10.4049/jimmunol.1300255 23836057 · DOI
  82. [84]de Charette M Marabelle A Houot R. Turning tumour cells into antigen presenting cells: the next step to improve cancer immunotherapy? Eur J Cancer. (2016) 68: 134– 47. 10.1016/j.ejca.2016.09.010 27755997 · DOI
  83. [85]Garrido F Aptsiauri N Doorduijn EM Garcia Lora AM van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. (2016) 39: 44– 51. 10.1016/j.coi.2015.12.007 26796069 PMC5138279 · DOI · Paper page
  84. [86]Gentles AJ Newman AM Liu CL Bratman SV Feng W Kim D. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. (2015) 21: 938– 45. 10.1038/nm.3909 26193342 PMC4852857 · DOI
  85. [87]Greenwald RJ Freeman GJ Sharpe AH. The B7 family revisited. Annu Rev Immunol. (2005) 23: 515– 48. 10.1146/annurev.immunol.23.021704.115611 15771580 · DOI · Paper page
  86. [88]Ribas A Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. (2018) 359: 1350– 5. 10.1126/science.aar4060 29567705 PMC7391259 · DOI · Paper page
  87. [89]Zou W Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. (2008) 8: 467– 77. 10.1038/nri2326 18500231 · DOI · Paper page
  88. [91]Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med. (2015) 373: 1490– 2. 10.1056/NEJMp1510079 26348216 · DOI
  89. [92]Waitz R Solomon SB Petre EN Trumble AE Fasso M Norton L. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. (2012) 72: 430– 9. 10.1158/0008-5472.CAN-11-1782 22108823 PMC4526218 · DOI
  90. [93]den Brok MH Sutmuller RP Nierkens S Bennink EJ Frielink C Toonen LW. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer. (2006) 95: 896– 905. 10.1038/sj.bjc.6603341 16953240 PMC2360548 · DOI
  91. [94]Kim DW Haymaker C McQuail N Sirmans E Spencer C Glitza I Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM). J ImmunoTher Cancer. (2015) 3: P137 10.1186/2051-1426-3-S2-P137 · DOI
  92. [95]McArthur HL Diab A Page DB Yuan J Solomon SB Sacchini V. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res. (2016) 22: 5729– 37. 10.1158/1078-0432.CCR-16-0190 27566765 PMC5161031 · DOI
  93. [96]Kato T Iwasaki T Uemura M Nagahara A Higashihara H Osuga K. Characterization of the cryoablation-induced immune response in kidney cancer patients. Oncoimmunology. (2017) 6: e1326441. 10.1080/2162402X.2017.1326441 28811963 PMC5543848 · DOI
  94. [97]Glazer DI Tatli S Shyn PB Vangel MG Tuncali K Silverman SG. Percutaneous image-guided cryoablation of hepatic tumors: single-center experience with intermediate to long-term outcomes. AJR Am J Roentgenol. (2017) 209: 1381– 9. 10.2214/AJR.16.17582 28952807 PMC5698169 · DOI
  95. [98]Packard AT Broski SM Callstrom MR Atwell TD Schmit GD Schmitz JJ. Utility of PET/CT after cryoablation for early identification of local tumor progression in osseous metastatic disease. AJR Am J Roentgenol. (2017) 208: 1342– 51. 10.2214/AJR.16.17222 28333548 · DOI
  96. [99]Permpongkosol S Nicol TL Khurana H Link RE Zhai QJ Kavoussi LR. Thermal maps around two adjacent cryoprobes creating overlapping ablations in porcine liver, lung, and kidney. J Vasc Interv Radiol. (2007) 18: 283– 7. 10.1016/j.jvir.2006.12.008 17327563 · DOI
  97. [100]Permpongkosol S Nicol TL Link RE Varkarakis I Khurana H Zhai QJ. Differences in ablation size in porcine kidney, liver, and lung after cryoablation using the same ablation protocol. AJR Am J Roentgenol. (2007) 188: 1028– 32. 10.2214/AJR.06.0810 17377040 · DOI
  98. [101]Marin-Acevedo JA Dholaria B Soyano AE Knutson KL Chumsri S Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. (2018) 11: 39. 10.1186/s13045-018-0582-8 29544515 PMC5856308 · DOI
  99. [102]Mayes PA Hance KW Hoos A. The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. (2018) 17: 509– 27. 10.1038/nrd.2018.75 29904196 · DOI
  100. [103]de Baere T Tselikas L Deschamps F Soria JC Marabelle A. Immuno-oncology in cancer care is a fantastic opportunity for interventional oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative. Cardiovasc Intervent Radiol. (2018) 41: 825– 7. 10.1007/s00270-018-1935-y 29549416 · DOI
  101. [104]Marabelle A Tselikas L de Baere T Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. (2017) 28: xii33– 43. 10.1093/annonc/mdx683 29253115 · DOI
  102. [105]Rosenberg MA Williams J Image guided cryoablation of cancer with intra-tumoral injection of anti-CTLA-4 and PD-1 immune check-point inhibitors. J ImmunoTher Cancer. (2015) 3: P142 10.1186/2051-1426-3-S2-P142 · DOI
  103. [106]Haanen J. Converting cold into hot tumors by combining immunotherapies. Cell. (2017) 170: 1055– 6. 10.1016/j.cell.2017.08.031 28886376 · DOI
  104. [107]Mizukami Y Kono K Maruyama T Watanabe M Kawaguchi Y Kamimura K. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer. (2008) 99: 1462– 7. 10.1038/sj.bjc.6604715 18841157 PMC2579690 · DOI
  105. [108]Newick K O'Brien S Moon E Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. (2017) 68: 139– 52. 10.1146/annurev-med-062315-120245 27860544 · DOI · Paper page
  106. [109]Angelova M Mlecnik B Vasaturo A Bindea G Fredriksen T Lafontaine L. Evolution of metastases in space and time under immune selection. Cell. (2018) 175: 751– 65 e716. 10.1016/j.cell.2018.09.018 30318143 · DOI

Authors
Yakkala, C., Chiang, C. L.-L., Kandalaft, L., Denys, A., & Duran, R.
Affiliations
  • Centre Hospitalier Universitaire Vaudois (CH)
  • University of Lausanne (CH)
  • Ludwig Cancer Research (CH)
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2019-09-24
Volume
10
Pages
2283-2283
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2019.02283
PMC
PMC6769045
OpenAlex
W2976986038
Cited by
88
References
113
Citations by year
2026: 9 · 2025: 14 · 2024: 14 · 2023: 21 · 2022: 12 · 2021: 10 · 2020: 8
FWCI
0.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, cc-by)
  • IRIS (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
Keywords
cryoablation, immunotherapy, tumor immunogenicity, tumor antigens, antitumor immunity, solid tumors, metastatic disease, combination therapy, cancer immunotherapy
MeSH terms
Antigens, Neoplasm, Clinical Trials as Topic, Combined Modality Therapy, Cryosurgery, Humans, Immune System, Immunotherapy, Neoplasms, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review